N/A N=25 Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes
Type 2 Diabetes
Primary: Change in HbA1c — -0.46; -0.58 Percentage of HbA1c
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=488 Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Bipolar Depression · Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.1; -12.4 score on a scale — p=<0.0001
N/A N=31 Technology Based Sedentary Reduction Intervention in Patients With Type 2 Diabetes
Type 2 Diabetes · Sedentary Behavior · Physical Activity
Primary: Level of Satisfaction With the Intervention Assessed by Lyons et al and Burner et al.'s Questionnaires — 5; 4; 5; 4 score on a scale
N/A N=98 EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study
Abdominal Aortic Aneurysm Without Rupture
Primary: Safety: Major Adverse Events (MAE) — 1; 2; 2 Number of Events
N/A N=30 EEG Personalized Transcranial Magnetic Stimulation (eTMS) for Post-Traumatic Stress Disorder
Stress Disorders, Post-Traumatic
Primary: Number, Severity, Relatedness, Type, Subsequent Treatment/Intervention Required, and Resolution Status of Adverse Events (AEs) During the Study. — 26; 3; 2; 17 Number of…
N/A N=30 Healthy Eating for My Infant (HEMI)
Pediatric Obesity
Primary: Group Differences in Infant BMI — 5; 2; 9; 11 Participants
N/A N=280 PRenatal Video-Based Education and PostPARtum Effects
Breastfeeding
Primary: Breastfeeding Exclusivity — 67; 84 Participants — p=.1200
N/A N=89 Glucose Variability in Type 1 Diabetes (T1D) and Glycaemic Responses to Food Composition.
Type 1 Diabetes
Primary: Mean Postprandial Glucose — 9.2 mmol/l
N/A N=186 BIOTRONIK Conduction System Pacing With the Solia Lead
Bradycardia · Atrioventricular Block · Left Bundle-Branch Block
Primary: Serious Adverse Device Effect (SADE)-Free Rate at 3 Months — 98 Percentage of participants without SADE — p=<0.0001
Phase 2 N=151 A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Social Anxiety Disorder
Primary: Change From Baseline to the Average Subjective Units of Distress Scale (SUDS) Score of the 5-minute Performance Phase of a Public Speaking Challenge — 22.42; 24.26…
Phase 2 N=200 Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 1 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
N/A N=308 Self-Management Intervention: Considering Needs & Preferences of Dementia Caregivers (Caregiver Career Study)
Stress · Carer Stress Syndrome · Dementia
Primary: Change in Caregiver's Perceived Stress Scale — 19.73; 21.01; 19.84; 19.21 score on a scale
N/A N=201 RHA®4 for Midface Volume Deficiency
Cheek Augmentation · Correction of Age-related Midface Contour Deficiencies
Primary: Non-inferiority of RHA®4 to the Change From Baseline for Subjects Treated With Comparator Product at 8 Weeks After the Last Treatment as Assessed by the BLE Using the…
Phase 3 N=302 Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) Score After 48 Weeks. — -11.2; -10.8 units on a scale
Phase 1 N=86 PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Part 1: Number of Participants With Drug Limiting Toxicities (DLTs) Graded According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)…